

02 February 2016 EMA/HMPC/150848/2015 Committee on Herbal Medicinal Products (HMPC)

# European Union herbal monograph on Valeriana officinalis L., radix

Final

Initial assessment	
Discussion in Working Party on European Union monographs and list	May 2005
(MLWP)	June 2005
	September 2005
Adoption by Committee on Herbal Medicinal Products (HMPC) for	20 September 2005
release for consultation	
End of consultation (deadline for comments)	31 January 2006
Re-discussion in MLWP	May 2006
	July 2006
Adoption by HMPC	13 July 2006
Monograph (EMEA/HMPC/340719/2005)	
AR (EMEA/HMPC/167391/2006)	
List of references (EMEA/HMPC/167392/2006)	
Overview of comments received during the public consultation	
(EMEA/HMPC/50774/2006)	
HMPC Opinion (EMEA/HMPC/313368/2006)	
First systematic review	
Discussion in MLWP	January 2015
	March 2015
	May 2015
Adopted by HMPC for release for consultation	7 July 2015
Start of public consultation	22 July 2015
End of consultation (deadline for comments)	31 October 2015
Re-discussion in MLWP	November 201
Adoption by HMPC	2 February 201

Keywords	Herbal medicinal products; HMPC; European Union herbal monographs; well-
	established medicinal use; traditional use; Valeriana officinalis L., radix;
	Valerianae radix; Valerian root

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact



An agency of the European Union

© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged.

BG (bulgarski): Валериана, корен	LT (lietuvių kalba): Valerijonų šaknys
CS (čeština): kozlíkový kořen	LV (latviešu valoda): Baldriāna saknes
DA (dansk): Baldrianrod	MT (Malti): Għerq tal-Valerjana
DE (Deutsch): Baldrianwurzel	NL (Nederlands): Valeriaanwortel
EL (elliniká): Ρίζα βαλεριανής	PL (polski): Korzeń kozłka
EN (English): Valerian root	PT (português): Valeriana, raiz
ES (español): Valeriana, raíz de	RO (română): rădăcină de valeriană
ET (eesti keel): palderjanijuur	SK (slovenčina): Koreň valeriány
FI (suomi): rohtovirmajuuri, juuri	SL (slovenščina): korenina zdravilne špajke
FR (français): Valériane (racine de)	SV (svenska): Vänderot, rot
HR (hrvatski): odoljenov korijen	IS (íslenska):
HU (magyar): Macskagyökér	NO (norsk): Valerianarot
IT (italiano): Valeriana radice	

## European Union herbal monograph on Valeriana officinalis L., radix

#### 1. Name of the medicinal product

To be specified for the individual finished product.

#### **2**. Qualitative and quantitative composition 1, 2

Well-established use	Traditional use
With regard to the marketing authorisation application of Article 10(a) of Directive 2001/83/EC as amended	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
Valeriana officinalis L., radix (Valerian root)	Valeriana officinalis L., radix (Valerian root)
i) Herbal substance Not applicable	i) Herbal substance Not applicable
ii) Herbal preparations Dry extract (DER 3-7.4:1), extraction solvent: ethanol 40-70% (V/V)	<ul> <li>ii) Herbal preparations</li> <li>a) Comminuted herbal substance</li> <li>b) Powdered herbal substance</li> <li>c) Expressed juice from fresh root (1:0.60- 0.85)</li> <li>d) Dry extract (DER 4-6:1), extraction solvent: water</li> <li>e) Liquid extract (DER 1:4-6), extraction solvent: water</li> <li>f) Dry extract (DER 4-7:1), extraction solvent: methanol 45% (V/V)</li> <li>g) Dry extract (DER 5.3-6.6:1), extraction solvent: methanol 45% (m/m)</li> <li>h) Liquid extract (DER 1:7-9), extraction solvent: sweet vine</li> <li>i) Liquid extract (DER 1:1), extraction solvent: ethanol 60% (V/V)</li> <li>j) Tincture (ratio of herbal substance to extraction solvent 1:8), extraction solvent: ethanol 56%</li> <li>l) Tincture (ratio of herbal substance to extraction solvent 1:5), extraction solvent: ethanol 70% (V/V)</li> </ul>

<sup>&</sup>lt;sup>1</sup> The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

<sup>&</sup>lt;sup>2</sup> The material complies with the Ph. Eur. monograph (ref.: 0453).

Well-established use	Traditional use
	<ul> <li>m) Tincture (ratio of herbal substance to extraction solvent 1:5), extraction solvent: ethanol 60-80% (V/V)</li> <li>n) Dry extract (DER 5.5-7.4:1), extraction solvent: ethanol 85% (m/m)</li> </ul>

#### 3. Pharmaceutical form

Well-established use	Traditional use
Herbal preparations in solid dosage forms for oral use.	Comminuted herbal substance as herbal tea for oral use.
The pharmaceutical form should be described by the European Pharmacopoeia full standard term.	Herbal preparation in liquid or solid dosage forms for oral use.
	Comminuted herbal substance for use as bath additive.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

#### 4. Clinical particulars

#### 4.1. Therapeutic indications

Well-established use	Traditional use
Herbal medicinal product for the relief of mild nervous tension and sleep disorders.	Traditional herbal medicinal product for relief of mild symptoms of mental stress and to aid sleep.
	The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use.

#### 4.2. Posology and method of administration<sup>3</sup>

Well-established use	Traditional use
Posology	Posology
Adolescents, adults and elderly	Adolescents, adults and elderly
Oral use	Oral use
Single dose: 400-600 mg dry extract; For relief of mild nervous tension up to 3 times daily.	<ul> <li>a) single dose: 0.3-3 g</li> <li>For relief of mild symptoms of mental stress</li> <li>up to 3 times daily.</li> <li>To aid sleep, a single dose half to one hour</li> </ul>

<sup>&</sup>lt;sup>3</sup> For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC 'Glossary on herbal teas' (EMA/HMPC/5829/2010 Rev.1).

Well-established use	Traditional use
For relief of sleep disorders, a single dose half to one hour before bedtime with an earlier dose during the evening if necessary. Maximum daily dose: 4 single doses	before bedtime with an earlier dose during the evening if necessary. Herbal tea: 0.3-3 g of the comminuted herbal substance in 150 ml of boiling water as a herbal infusion
The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').	<ul> <li>b) single dose: 0.3-2.0 g</li> <li>For relief of mild symptoms of mental stress up to 3 times daily.</li> </ul>
<b>Duration of use</b> Because of its gradual onset of efficacy valerian root is not suitable for acute interventional	To aid sleep, a single dose half to one hour before bedtime with an earlier dose during the evening if necessary.
treatment of mild nervous tension or sleep disorders. To achieve an optimal treatment effect, continued use over 2-4 weeks is recommended.	<ul> <li>c) single dose: 10 ml</li> <li>For relief of mild symptoms of mental stress up to 3 times daily.</li> <li>To aid sleep, a single dose half to one hour before bedtime with an earlier dose during</li> </ul>
If the symptoms persist or worsen after 2 weeks of continued use, a doctor or a pharmacist should be consulted.	<ul><li>d) single dose: 420 mg</li></ul>
Method of administration Oral use	For relief of mild symptoms of mental stress up to 3 times daily. To aid sleep, a single dose half to one hour before bedtime with an earlier dose during the evening if necessary.
	<ul> <li>e) single dose: 20 ml</li> <li>For relief of mild symptoms of mental stress up to 3 times daily.</li> <li>To aid sleep, a single dose half to one hour before bedtime.</li> </ul>
	<ul> <li>f) single dose: 144-288 mg</li> <li>For relief of mild symptoms of mental stress up to 4 times daily.</li> <li>To aid sleep, a single dose half to one hour before bedtime with an earlier dose during the evening if necessary.</li> </ul>
	<ul> <li>g) single dose: 450 mg</li> <li>For relief of mild symptoms of mental stress up to 3 times daily.</li> <li>To aid sleep, a single dose half to one hour before bedtime with an earlier dose during the evening if necessary.</li> </ul>
	h) single dose: 10 ml, up to 3 times daily
	i) single dose: 0.3-1.0 ml, up to 3 times daily
	j) single dose: 4-8 ml, up to 3 times daily

Well-established use	Traditional use
	k) single dose: 0.84 ml
	For relief of mild symptoms of mental stress 3-5 times daily.
	To aid sleep, a single dose half an hour before bedtime.
	<ul> <li>I) single dose: 1.5 ml (mental stress), 3 ml (to aid sleep)</li> <li>For relief of mild symptoms of mental stress up to 3 times daily.</li> <li>To aid sleep, a single dose half an hour before bedtime.</li> </ul>
	m) single dose: 10 ml, up to 3 times daily
	n) single dose: 322 mg, up to 3 times daily
	The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Use as bath additive
	a) single dose: 100 g for a full bath; up to 1 bath daily
	The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	<b>Duration of use</b> If symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	<b>Method of administration</b> Oral use
	Use as bath additive. Temperature: 34-37°C, duration of bath 10-20 minutes.

#### 4.3. Contraindications

Well-established use	Traditional use
Hypersensitivity to the active substance.	Hypersensitivity to the active substance.
	Use as bath additive
	Full baths are contraindicated in cases of open wounds, large skin injuries, acute skin diseases,

Well-established use	Traditional use
	high fever, severe infections, severe circulatory disturbances and cardiac insufficiency.

#### 4.4. Special warnings and precautions for use

Well-established use	Traditional use
The use is not recommended in children below 12 years of age due to a lack of data on safety and efficacy. If the symptoms worsen during the use of the medicinal product, a doctor or a pharmacist should be consulted.	The use in children under 12 years of age has not been established due to lack of adequate data. If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. For tinctures and extracts containing ethanol, the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be included.

### 4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
None reported	None reported

#### 4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, use during pregnancy and lactation is not recommended.
No fertility data available.	No fertility data available.

#### 4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
May impair ability to drive and use machines.	May impair ability to drive and use machines.
Affected patients should not drive or operate	Affected patients should not drive or operate
machinery.	machinery.

#### 4.8. Undesirable effects

Well-established use	Traditional use
Gastrointestinal symptoms (e.g. nausea, abdominal cramps) may occur after ingestion of valerian root preparations. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a pharmacist should be consulted.	Oral use Gastrointestinal symptoms (e.g. nausea, abdominal cramps) may occur after ingestion of valerian root preparations. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted. Use as bath additive None known If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted.

#### 4.9. Overdose

Well-established use	Traditional use
Valerian root at a dose of approximately 20 g caused symptoms such as fatigue, abdominal cramp, chest tightness, light-headedness, hand tremor and mydriasis, which disappeared within 24 hours. If symptoms arise, treatment should be supportive.	Oral use Valerian root at a dose of approximately 20 g caused symptoms, such as fatigue, abdominal cramp, chest tightness, light-headedness, hand tremor and mydriasis, which disappeared within 24 hours. If symptoms arise, treatment should be supportive. Use as bath additive No case of overdose has been reported.

#### 5. Pharmacological properties

#### 5.1. Pharmacodynamic properties

Well-established use	Traditional use
Pharmacotherapeutic group: Hypnotics and sedatives	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.
Proposed ATC code: N05C M09	
The sedative effects of preparations of valerian root, which have long been recognised empirically, have been confirmed in controlled clinical studies. Orally administered dry extracts of valerian root prepared with ethanol/water	

Well-established use	Traditional use
(ethanol maximum 70% (V/V)) in the	
recommended dosage have been shown to	
improve sleep latency and sleep quality. These	
effects cannot be attributed with certainty to any	
known constituents.	

#### 5.2. Pharmacokinetic properties

Well-established use	Traditional use
No data available.	Not required as per Article 16c(1)(a)(iii) of
	Directive 2001/83/EC as amended.

#### 5.3. Preclinical safety data

Well-established use	Traditional use
Ethanol extracts of valerian root have shown low toxicity in rodents during acute tests and from repeated dose toxicity over periods of 4-8 weeks.	AMES-tests on mutagenicity with extracts, representing the two extremes of the polarity range did not give any reason for concern.
AMES-tests on mutagenicity for the dry extract (4-7:1); extraction solvent ethanol 40% (V/V) and the dry extract (DER 3-6:1), extraction solvent ethanol 70% (V/V) did not give any reason for concern.	Tests on reproductive toxicity and carcinogenicity have not been performed.
Tests on reproductive toxicity and carcinogenicity have not been performed.	

#### 6. Pharmaceutical particulars

Well-established use	Traditional use
Not applicable	Not applicable

#### 7. Date of compilation/last revision

02 February 2016